scholarly journals PRS46 ASSOCIATION BETWEEN COMPLIANCE OF SEVERE ASTHMA PATIENTS WITH MAINTENANCE THERAPY AND IMPACT ON LEVEL OF DISEASE CONTROL AND FULL-TIME EMPLOYMENT

2019 ◽  
Vol 22 ◽  
pp. S357-S358
Author(s):  
A. Kyle ◽  
N.B. Yaacob ◽  
B.Y. Cheng ◽  
S. Brown ◽  
S. Heinz ◽  
...  
Keyword(s):  
Maintenance Therapy ◽  
Disease Control ◽  
Severe Asthma ◽  
Full Time ◽  
Asthma Patients ◽  
Full Time Employment

scholarly journals Patient and Physician Perspectives on Asthma and Its Therapy in Romania: Results of a Multicenter Survey

Medicina ◽  
2021 ◽  
Vol 57 (10) ◽  
pp. 1089
Author(s):  
Dragos Bumbacea ◽  
Carmen Panaitescu ◽  
Roxana Silvia Bumbacea
Keyword(s):  
Maintenance Therapy ◽  
Asthma Control ◽  
Severe Asthma ◽  
Asthma Management ◽  
Asthma Severity ◽  
Treatment Goals ◽  
Cross Sectional ◽  
Multicenter Survey ◽  
Patient Reported ◽  
Asthma Patients

Background and Objectives: Patient’s behaviours, attitudes and beliefs related to asthma and its treatment were shown to influence the adherence to therapy and the level of asthma control. This survey aimed to assess the level of asthma control and patient-reported behaviours, attitudes and expectations related to their disease in Romanian patients. Materials and Methods: This cross-sectional quantitative survey was performed in February-March 2019 and enrolled 70 specialist physicians experienced in asthma management and 433 asthma patients under their care. Results: Of the 433 patients enrolled, 19.4% had mild asthma, 60.5% moderate asthma and 20.1% severe asthma. For the previous 12 months, asthma symptoms, exacerbations and emergency room visits were common in the sample analysed, with significantly higher figures in severe asthma patients (p < 0.001). The most important treatment goal for asthma patients was participation in all activities of daily living, while for physicians this was preventing asthma exacerbations. The valuation of the treatment goals was different between patients with severe asthma and those with mild and moderate forms. Based on the patients’ responses, 3 attitude clusters were identified: empowered savvy (36.5% of the patients), pessimistic non-compliers (43.2%), and anxious strugglers (20.3%). “Empowered savvy” had the lowest frequency of severe asthma, the highest adherence to maintenance therapy and the highest level of confidence in the effectiveness of asthma medication. The opposite of this attitude cluster is the “anxious strugglers”, containing more patients with severe asthma, a higher score for worries about asthma therapy and better self-reported knowledge of their treatment, contrasting with a proportion of 25% taking maintenance therapy only when having breathing difficulties. Conclusion: Asthma control in Romania remains poor, with frequent exacerbations and hospitalizations. The differences in treatment goals found between patients and physicians and between different asthma severity groups suggest the need for more patient-centred approaches.

scholarly journals Real-life study in non-atopic severe asthma patients achieving disease control by omalizumab treatment

2020 ◽  
Author(s):  
Paloma Campo ◽  
jose gregorio Soto campos ◽  
Ana Moreira Jorge ◽  
Santiago Quirce ◽  
Alicia Padilla ◽  
...  
Keyword(s):  
Disease Control ◽  
Severe Asthma ◽  
Real Life ◽  
Life Study ◽  
Asthma Patients ◽  
Real Life Study

scholarly journals Real‐life study in non‐atopic severe asthma patients achieving disease control by omalizumab treatment

Allergy ◽  
2020 ◽  
Author(s):  
Paloma Campo ◽  
Gregorio Soto Campos ◽  
Ana Moreira ◽  
Santiago Quirce ◽  
Alicia Padilla‐Galo ◽  
...  
Keyword(s):  
Disease Control ◽  
Severe Asthma ◽  
Real Life ◽  
Life Study ◽  
Asthma Patients ◽  
Real Life Study

scholarly journals COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control

Vaccines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 853
Author(s):  
Marco Caminati ◽  
Gabriella Guarnieri ◽  
Veronica Batani ◽  
Elena Scarpieri ◽  
Anita Finocchiaro ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Disease Control ◽  
Severe Asthma ◽  
Vaccination Campaign ◽  
Tolerability Profile ◽  
Life Questionnaire ◽  
Biologic Treatment ◽  
Asthma Patients

Background: COVID-19 vaccination has been recommended for severe asthmatics. We aimed to evaluate the safety, tolerability, and impact on disease control and patient’s quality of life of the mRNA SARS-CoV-2/COVID-19 vaccine in severe asthma patients regarding biologic treatment. Methods: Severe asthmatic patients regularly managed by two big allergy and respiratory referral centers were offered to undergo Pfizer COVID 19 vaccination at the hospital site. Patients filled in an adverse events questionnaire after the first and second dose, as well as the Asthma Control Test (ACT) and Asthma Quality of Life Questionnaire (AQLQ). Results: Overall, 253 patients were vaccinated; only 16 patients refused. No serious events were detected. Less than 20% of patients reported side effects, most of which were classified as very common side effects. No differences were reported according to the ongoing biologic drug. A significant improvement in both ACT and AQLQ was observed between the first and the second dose administration. Conclusions: Our data confirm the optimal safety and tolerability profile of mRNA SARS- CoV-2/COVID-19 in severe asthma patients on biologic treatment, as well as their positive attitude towards COVID-19 vaccination. The negligible proportion of patients reporting side effects and the absence of asthma exacerbations are relevant to support the COVID-19 vaccination campaign in severe asthma patients worldwide.

Strict Adherence To A Follow-Up Improves Disease Control In Severe Asthma Patients

2011 ◽  
Author(s):  
Pierluigi Paggiaro ◽  
Federico L. Dente ◽  
Giulia Spoletini ◽  
Lorenza Melosini ◽  
Federica Novelli ◽  
...  
Keyword(s):  
Disease Control ◽  
Severe Asthma ◽  
Strict Adherence ◽  
Asthma Patients

Coping experiences of graduate students on full-time employment and full-time academic programmes

2020 ◽  
Vol 39 (5-6) ◽  
pp. 605-618
Author(s):  
Samuel Amponsah ◽  
Alex Kumi-Yeboah ◽  
Stephen O. Adjapong ◽  
Chris Olusola Omorogie
Keyword(s):  
Graduate Students ◽  
Full Time ◽  
Full Time Employment

scholarly journals Comparing Patient Characteristics, Clinical Outcomes, and Biomarkers of Severe Asthma Patients in Taiwan

Biomedicines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 764
Author(s):  
Shih-Lung Cheng ◽  
Kuo-Chin Chiu ◽  
Hsin-Kuo Ko ◽  
Diahn-Warng Perng ◽  
Hao-Chien Wang ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Clinical Characteristics ◽  
Linear Models ◽  
Patient Characteristics ◽  
Emergency Department Visits ◽  
Receiver Operating Characteristic Curves ◽  
Increased Risk ◽  
Significant Difference ◽  
Asthma Patients ◽  
Patients At Risk

Purpose: To understand the association between biomarkers and exacerbations of severe asthma in adult patients in Taiwan. Materials and Methods: Demographic, clinical characteristics and biomarkers were retrospectively collected from the medical charts of severe asthma patients in six hospitals in Taiwan. Exacerbations were defined as those requiring asthma-specific emergency department visits/hospitalizations, or systemic steroids. Enrolled patients were divided into: (1) those with no exacerbations (non-exacerbators) and (2) those with one or more exacerbations (exacerbators). Receiver operating characteristic curves were used to determine the optimal cut-off value for biomarkers. Generalized linear models evaluated the association between exacerbation and biomarkers. Results: 132 patients were enrolled in the study with 80 non-exacerbators and 52 exacerbators. There was no significant difference in demographic and clinical characteristics between the two groups. Exacerbators had significantly higher eosinophils (EOS) counts (367.8 ± 357.18 vs. 210.05 ± 175.24, p = 0.0043) compared to non-exacerbators. The optimal cut-off values were 292 for EOS counts and 19 for the Fractional exhaled Nitric Oxide (FeNO) measure. Patients with an EOS count ≥ 300 (RR = 1.88; 95% CI, 1.26–2.81; p = 0.002) or FeNO measure ≥ 20 (RR = 2.10; 95% CI, 1.05–4.18; p = 0.0356) had a significantly higher risk of exacerbation. Moreover, patients with both an EOS count ≥ 300 and FeNO measure ≥ 20 had a significantly higher risk of exacerbation than those with lower EOS count or lower FeNO measure (RR = 2.16; 95% CI, 1.47–3.18; p = < 0.0001). Conclusions: Higher EOS counts and FeNO measures were associated with increased risk of exacerbation. These biomarkers may help physicians identify patients at risk of exacerbations and personalize treatment for asthma patients.

Sign in / Sign up

Export Citation Format

Share Document